| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/20/2002 | WO2001070231A3 Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries |
| 06/20/2002 | WO2001068068A3 Compounds capable of binding with the cytoskeleton |
| 06/20/2002 | WO2001068066A3 A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer |
| 06/20/2002 | WO2001064755A3 Isoxazole gegen virale erkrankungen |
| 06/20/2002 | WO2001060326A3 Cosmetic or pharmaceutical composition containing sesquiterpene lactone |
| 06/20/2002 | WO2001054771A3 Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 06/20/2002 | WO2001052860A3 Method and composition for modulating an immune response |
| 06/20/2002 | WO2001052837A3 Use of at least a fatty ester for preparing a composition designed to inhibit 5-$g(a)-reductase activity, in pharmacology, in particular dermatology, in cosmetics and as food additive |
| 06/20/2002 | WO2001051633A3 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 06/20/2002 | WO2001047528A3 Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes |
| 06/20/2002 | WO2001047505A3 Use of azoles for preventing skin cancer |
| 06/20/2002 | WO2001044445A8 Human lyases and associated proteins |
| 06/20/2002 | WO2001037818A3 Medicament and combination of compatible medicaments |
| 06/20/2002 | WO2001030328A3 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions |
| 06/20/2002 | WO2001022917A8 Effervescent compositions comprising nimesulide |
| 06/20/2002 | WO2001014576A8 Process and intermediates for the preparation of isoxazolecaroxamides and analogues |
| 06/20/2002 | WO2001003688A3 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 06/20/2002 | WO2000077233A9 Complement-resistant non-mammalian dna viruses and uses thereof |
| 06/20/2002 | WO2000076451A3 Pharmaceutical composition comprising no or at least a no donor compound inducing no formation in cells |
| 06/20/2002 | WO2000067734A3 Use of phthalazine derivatives |
| 06/20/2002 | WO2000061596A8 50 human secreted proteins |
| 06/20/2002 | WO2000052210A9 Methods for targeting rna molecules |
| 06/20/2002 | WO2000050031A9 Co-administration of lucanthone and radiation for treatment of cancer |
| 06/20/2002 | US20020077506 For therapy of inflammatory or painful disorder |
| 06/20/2002 | US20020077486 Platelet ADP receptor inhibitors |
| 06/20/2002 | US20020077482 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives |
| 06/20/2002 | US20020077476 Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia |
| 06/20/2002 | US20020077465 Nuceotide sequences coding enzymatic polypeptide for use in the treatment and prevention of inflammation, cancer, muuscle disorders and thrombosis |
| 06/20/2002 | US20020077461 Pharmaceutical formulation |
| 06/20/2002 | US20020077366 Novel cationic amphiphiles containing N-hydroxyalkyl group for intracellular delivery of biologically active molecules |
| 06/20/2002 | US20020077365 Method for increasing the effectiveness of antiinfective |
| 06/20/2002 | US20020077364 Thyroid hormone formulations |
| 06/20/2002 | US20020077362 Higher unsaturated fatty acid composition |
| 06/20/2002 | US20020077361 Can be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects |
| 06/20/2002 | US20020077360 Administering to a mammal a retinoid campound which binds specifically or selectively to a RAR alpha retinoid receptors in preference over RAR beta and RAR Gamma retinoid receptors, for therapy and prophylaxisof disease or condition |
| 06/20/2002 | US20020077359 Therapy of patients with orally administration of dosage of 13 cis- retinoic acid daily for a period from about ten days to about twenty days, and followed by a sustaining treatment by administering 13 cis- retinoic acid for five to seven days |
| 06/20/2002 | US20020077358 Administering hydroxyeicosatetraenoic acid derivatives that stimulate mucin production and/or secretion in the conjunctival epithelium for the treatment of transient dry eye conditions associated with refractive surgery |
| 06/20/2002 | US20020077357 For therapy of autoimmune disease |
| 06/20/2002 | US20020077356 Nonsteroidal antiinflammatory agents |
| 06/20/2002 | US20020077355 Administering to a subject having a cerebrovascular condition, an epoxyeicosatrienoic acid in an amount effective to reduce brain injury |
| 06/20/2002 | US20020077354 Methods and compositions for stabilizing oxidizable compounds |
| 06/20/2002 | US20020077353 Reacting 1-(3-Dimethylamino-1-propyl)-1-(4-fluorophenyl)-5-((trifluoromethyl)sulfonyl-oxy)-1,3-dihydroisobenzofurane or 1-(4'-fluorophenyl)-1- (3-dimethylaminopropyl)-5-bromophtalane with with a cyanide source in presence of palladium catalyst |
| 06/20/2002 | US20020077352 N-methyl-D-aspartate receptor antagonists |
| 06/20/2002 | US20020077351 For therapy and prophylaxis of diseases such as cachexia attributed to cancer or infections, rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus, rejection during bone marrow transplantation |
| 06/20/2002 | US20020077350 Compositions exhibiting synergistic inhibition of the expression and/or activity of clyclooxygenase-2 |
| 06/20/2002 | US20020077349 Method of treating age-related vision impairment |
| 06/20/2002 | US20020077348 Dosage unit for cardioprotection |
| 06/20/2002 | US20020077346 For therapy of inflammatory and pain of a traumatic or pathologic origin |
| 06/20/2002 | US20020077345 Cis-substituted aminocycloalkylpyrrolidine derivatives |
| 06/20/2002 | US20020077344 For therapy and prophylaxis of high blood pressure, cardiac hypertrophy, cardiac insufficiency, coronary heart diseases such as angina pectoris, cardiac infarct, vascular restenosis after angioplasty, cardiomyopathies, endothelial dysfunction |
| 06/20/2002 | US20020077343 H2 receptor antagonist compounds in combination with nitric oxide donors, compostions and methods of use |
| 06/20/2002 | US20020077342 For use in therapy of epilepsy, depression, tension, gastrointestinal disorders, pain, inflammation |
| 06/20/2002 | US20020077341 C10 carbamoyloxy substituted taxanes |
| 06/20/2002 | US20020077340 Pyridone inhibitors of fatty acid binding protein and method |
| 06/20/2002 | US20020077339 Chemokine receptor binding heterocyclic compounds |
| 06/20/2002 | US20020077338 HIV protease inhibitors |
| 06/20/2002 | US20020077337 Chemical compounds |
| 06/20/2002 | US20020077335 For therapy of asthma, chronic obstructive pulmonary disease, airway hyperreactivity, skin disorders and itch (for example, atopic dermatitis and cutaneous wheal and flare), neurogenic inflammation and Parkinson's disease, psychosis |
| 06/20/2002 | US20020077334 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| 06/20/2002 | US20020077333 For therapy inflammation, inflammatory diseases, immunologic diseases and other diseases mediated by tumor necrosis factor-alpha (TNF-alpha) and/or interleukin 6 or 10 and/or enzyme cyclooxygenase-2 (COX-2) |
| 06/20/2002 | US20020077332 Zolpidem hemitartrate |
| 06/20/2002 | US20020077330 For therapy of tumoral diseases, diseases of the lungs and respiratory tract |
| 06/20/2002 | US20020077329 EP4 receptor inhibitors to treat rheumatoid arthritis |
| 06/20/2002 | US20020077328 Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain |
| 06/20/2002 | US20020077326 (S)-hydroxynefazodone antipsychotic therapy |
| 06/20/2002 | US20020077325 New camptothecin analogue compounds |
| 06/20/2002 | US20020077324 Novel polyhydroxypyrazine derivatives, their preparation and the pharmaceutical compostions which comprise them |
| 06/20/2002 | US20020077323 Use of delta opioid receptor ligands and serotonin reuptake inhibitors in the treatment of chemical dependencies |
| 06/20/2002 | US20020077322 Protection of neurons against glutamate-induced damage in glaucoma and other conditions |
| 06/20/2002 | US20020077321 For therapy of tumor metastasis, solid tumor growth (neoplasia), osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, osteopenia, angiogenesis, including tumor angiogenesis and lymphangiogenesis |
| 06/20/2002 | US20020077320 For use as hypolipidemic, antihyperglycemic compounds |
| 06/20/2002 | US20020077319 Combination of GABA agonists and aldose reductase inhibitors |
| 06/20/2002 | US20020077318 Substituted azepino[4,5b] indoline derivatives |
| 06/20/2002 | US20020077317 For use in therapy of hyperglycemia, cancer, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, scleroderma, corneal diseases, diabetic retinopathy associated with neovascularization, macular degenration, ovulation |
| 06/20/2002 | US20020077316 For therapy and prophylaxis of cardiovascular disease, dyslipidemia; dyslipoproteinemia; disorder of glucose metabolism; Alzheimer's Disease; Syndrome X; peroxisome proliferator activated receptor-associated disorder |
| 06/20/2002 | US20020077314 Use of hyaluronic acid and forms to prevent arterial restenosis |
| 06/20/2002 | US20020077313 Methods and compositions for the diagnosis and treatment of cancer |
| 06/20/2002 | US20020077305 Genetic immunization with cationic lipids |
| 06/20/2002 | US20020077304 Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds |
| 06/20/2002 | US20020077301 Administering combination of farnesyl transferase inhibitor (FTI) and signal transduction inhibitor (STD in a therapeutically effective amount, wherein proliferation of cells is reduced and/ or apoptosis of cells is enhanced |
| 06/20/2002 | US20020077299 Combinations of sesquiterpene lactones and ditepene triepoxide lactones for synergistic inhibition of cyclooxygenase-2 |
| 06/20/2002 | US20020077291 Method of treatment of tumors using transforming growth factor-alpha |
| 06/20/2002 | US20020077279 Manufacture of polyglutamate-therapeutic agent conjugates |
| 06/20/2002 | US20020077278 Administering glatiramer acetate (Copolymer 1) to the subject for therapy of inflammatory, non-autoimmune central nervous system diseases |
| 06/20/2002 | US20020077274 Administering therapeutically effective amount of a compound that inhibits cGMP-specific phosphodiesterase (PDE5) for therapy of Parkinson's disease |
| 06/20/2002 | US20020077273 Methods of using agents that modulate bone formation and inhibit adipogenesis |
| 06/20/2002 | US20020077272 Contacting bacteria with an agent that alters the bacteria's native level of DNA methyltransferase (Dam) activity thereby altering the bacteria's native level of methylation of adenine in a GATC tetranucleotide of the bacteria |
| 06/20/2002 | US20020077271 Compounds and methods of use to treat infectious diseases |
| 06/20/2002 | US20020077270 Nucleic acids, proteins, and antibodies |
| 06/20/2002 | US20020076821 Monitoring iron-complex products; obtain heme containing chemical product, subjet to a variety of spectrum analyses, compare to control |
| 06/20/2002 | US20020076810 Biocompatible composition in the form of a gel for use in the treatment of, inflammation,tumors and bone disorders |
| 06/20/2002 | US20020076796 2786, a novel human aminopeptidase |
| 06/20/2002 | US20020076795 Novel TRF1 binding protein, methods of use thereof |
| 06/20/2002 | US20020076793 Interleukin-1 beta converting enzyme like apoptosis protease-3 and 4 |
| 06/20/2002 | US20020076781 Regulation of intracellular glucocorticoid concentrations |
| 06/20/2002 | US20020076766 Novel glucosaminidase |
| 06/20/2002 | US20020076750 Peptide for use as tools in human therapeutics and diagnostics |
| 06/20/2002 | US20020076712 Human RNase H and compositions and uses thereof |
| 06/20/2002 | US20020076702 Evaluating prostaglandin response to preferential modulators; obtain sample, incubate with modulator, compare profile with control, determine if human had prostaglandin response to moduator based on differences in control and sample profiles |
| 06/20/2002 | US20020076469 Composition and method |